Investor Reminder: Capricor Therapeutics (NASDAQ:CAPR) Investors are Encouraged to Contact BFA Law – Securities Fraud Lawsuit Pending Over Mine Production Issues
Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading to a 64%